Aims To investigate whether a low heart rate is necessary to maintain improvement in myocardial function after long-term treatment with a beta-blocker in patients with heart failure.
Methods and Results
Forty-eight patients with congestive heart failure were investigated: 30 patients with dilated cardiomyopathy participating in a placebo-controlled trial (15 on placebo, 15 on metoprolol), and 18 patients treated by metoprolol in an open protocol. Investigations of spontaneous heart rate and of matched paced heart rates were performed at baseline and after 3, 6 and 12 months of follow-up by radionuclide angiography. There were significant signs of improvement in systolic indices of the spontaneous heart rate in the metoprolol-treated group (peak ejection rate: 0·98 to 1·32 end-diastolic volume . s 1 , P=0·015) as compared to placebo (1·14 to 1·19 enddiastolic volume . s 1 , not significant). Similar effects were observed during the matched paced heart rate (peak ejection rate: metoprolol 0·91 to 1·38 end-diastolic volume . s 1 , P=0·037; placebo 1·22 to 1·12 end-diastolic volume . s 1 , not significant). No effects were observed in the early peak filling rate. Left ventricular volumes decreased during metoprolol treatment, both for the spontaneous heart rate and during matched pacing.
Introduction
Congestive heart failure is accompanied by a disadvantageous increase in heart rate [1] , and also by chronotropic incompetence [2] . Reduction in heart rate is an obvious beneficial effect achieved by beta-blockade treatment. However, whether heart rate reduction is the major effect, and whether this is mandatory to maintain the improved cardiac function has not been established. There are several plausible beneficial effects of a reduced heart rate in the failing heart, such as the lengthening of diastole and the improvement in subendocardial perfusion [3] [4] [5] [6] . Further, it has been shown that beta-blockade tends to improve myocardial energetics in congestive heart failure, independent of a reduction in heart rate [7] [8] [9] . Other than effects on diastole and myocardial metabolism, experimental data performed on isolated myocardial strips and intact hearts have suggested that a decrease in contraction frequency might improve systolic function [10, 11] . The aim of the present study was to investigate whether treatment effects of longterm beta-blockade was dependent on a lower heart rate. Originating from our earlier observations [7, 12] , we hypothesized that positive effects achieved by long-term beta-blockade would be, in part, independent of heart rate reduction. The positive effects of beta-blockade on cardiac function has been shown, and the aim of this study was to increase the understanding of the effects of beta-blocker in heart failure treatment.
Methods
The patients in the present study were, in part, recruited from the Metoprolol in Dilated Cardiomyopathy trial [13] . The main study enrolled 383 patients in a double-blind randomized, placebo-controlled trial, stratified according to investigating centre and ejection fraction (<20% or 20% to 39%, respectively). Patients with symptomatic idiopathic dilated cardiomyopathy and an ejection fraction <40% were eligible for the study. Exclusion criteria were: coronary artery disease confirmed by coronary arteriography; systemic disease; insulin-dependent diabetes mellitus; excessive alcohol consumption; hypertension; signs of active myocarditis; or other serious disease that might influence the prognosis of the patient. In the present study, performed at the coordinating centre at Sahlgrenska University Hospital, 15 patients were randomized to placebo, and 15 to metoprolol.
Parallel to the placebo-controlled Metoprolol in Dilated Cardiomyopathy trial, 18 patients were enrolled in an open protocol, with titration schedule and follow-up investigations similar to the double-blind trial. All these 18 patients presented with an echocardiographic picture of dilated cardiomyopathy and were investigated for participation in the Metoprolol in Dilated Cardiomyopathy trial. During the screening investigation it was discovered that the patients met one or more of the exclusion criteria in this trial. The reasons for not including these patients in the double-blind study were: ejection fraction above 40% in two, significant coronary stenosis on the angiocardiogram in eight, insulin-dependent diabetes mellitus in one, systemic collagenosis in one, muscular dystrophy in one, a recently completed placebo period in a previous drug trial in three, and domiciled outside the catchment area of the hospital in two. Twelve of the 18 patients in the open protocol were followed for 6 months, and six patients were followed for 12 months.
Titration of study medication was performed according to the following schedule: week 1, 5 mg twice daily; week 2, 5 mg three times daily; week 3, 10 mg three times daily; week 4, 25 mg twice daily; week 5, 25 mg three times daily; week 6, 50 mg twice daily; week 7 and onward, 50 mg three times daily. The dose at the end of the study was 142 18 mg . day 1 The period of treatment was 12 months, and investigations were performed at baseline and after 3, 6 and 12 months of treatment. Baseline characteristics are given in Table 1 . The double-blind metoprolol group was younger than the other two groups. There were otherwise no significant differences between the three groups at baseline.
Investigations
Radionuclide investigation Equilibrium radionuclide angiocardiography was performed at rest. Red blood cells were labelled with 925 MBq of technetium-99 m using standard in vivo-in vitro labelling techniques. Imaging was performed with a small field of view single-crystal gamma camera in the left anterior oblique position that best separated the right and left ventricles, and with a 20 caudal tilt. Data were collected using 33 frames per RR interval, with ECG tolerance 10% of the cardiac cycle, with exclusion of extrasystolic and post-extrasystolic cycles. The acquisition was stopped when the left ventricular region of interest contained approximately 150 counts per pixel.
Atrial pacing
To offset the long-term reduction in heart rate induced by metoprolol treatment, transoesophageal atrial pacing was performed by an external pacemaker (Arzco Medical Electronics, Chicago, U.S.A.). It was not possible to achieve atrial pacing in all patients, either due to non-capture or because the patient did not tolerate pacing and/or the oesophageal electrode. Pacing was P=statistical significance comparing the metoprolol groups with the placebo group.
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accomplished in 12 placebo and 30 metoprolol patients at baseline (double-blind 14; open treatment 16). The patient swallowed an electrode capsule and the electrode was adjusted to a position behind the atria. Radionuclide angiography was performed during spontaneous heart rhythm and during pacing, with the pacing frequency approximately 10 beats above the spontaneous heart rate at baseline investigation. During follow-up investigations, the pacing rate was adjusted to obtain stable capture and a matched pacing frequency was aimed for. Systemic blood pressure was measured using a right arm cuff sphygmomanometer. Heart rate was measured from the ECG recorded on a Siemens Elema Mingograph 82. Blood pressure and heart rate were recorded at the beginning and at the end of each acquisition period, and the mean value of the two measurements was used in the present analysis.
Measurements
The radionuclide investigations were evaluated by two blinded investigators, who were unaware of patient identity, treatment, and time of investigation. A left ventricular time-activity curve was generated using a semi-automated edge-detecting algorithm with varying regions of interest. Ejection fraction, maximal peak ejection rate, and maximal diastolic early peak filling rate, expressed as end-diastolic volume per second, were calculated from the left ventricular time-activity curve after background subtraction and filtering by a polynomial fit which retained only the first three harmonics of the curve. Left ventricular volumes were estimated using a ratio between the total counts and the counts in the hottest pixel recorded from the left ventricular region of interest [14, 15] .
Statistical methods
Due to non-normal distribution of data, non-parametric tests were used. Within-group effects were evaluated by the Wilcoxon signed rank test. Differences between groups were assessed by the Mann-Whitney rank sum test, comparing changes from baseline to follow-up investigations. No correction for multiple testing was made. All P-values are expressed as mean SEM.
The study was approved by the Ethics Committee of the Medical Faculty, Gö teborg University. Participating patients gave informed consent before inclusion in the study.
Results

Compliance
During the study there were three deaths: one placebo patient died after 45 days of treatment and was investigated at baseline only. This patient is not included in the analysis. One metoprolol patient died suddenly after 6 months of treatment, and one patient (placebo) was withdrawn because of non-compliance after 6 months of treatment and died subsequently before the end of the study.
Evaluation at spontaneous heart rate Table 2 Heart rate decreased by an average 6 beats . min 1 from baseline to 12 months follow-up in the placebo group, and by 13 beats in the metoprolol treated group. Patients on open treatment showed a more pronounced decrease in heart rate, from 85 to 69 beats . min 1 as compared to the metoprolol (86 to 77) and placebo treated patients (89 to 83) in the double-blind arm of the trial. Systolic blood pressure was virtually unchanged in the placebo group, whereas it gradually increased in the beta-blocker treated patients during follow-up (Fig. 1) .
Ejection fraction improved significantly in the metoprolol-treated patients, from 27 1·8% to 34 2·7%, P=0·003 (Fig. 2) . The patients on open treatment started from a higher baseline level of ejection fraction, but had a similar increase in terms of units (+8 units) of increment as compared with the patients on blind metoprolol medication (+7 units).
Peak ejection rate, expressing systolic performance, displayed a significant increase in the metoprolol group from 3 months and onward. There were no significant changes in diastolic early peak filling rate in either group. Left ventricular volumes -end-systolic volume in particular -decreased in both studied groups on beta-blockade. Placebo-treated patients had no change in ventricular volumes during the study. Table 3 The atrial pacing rate was kept between 100 and 107 beats . min 1 during the investigations, and without statistical significant differences between the two groups. Although with small absolute differences, the pacing rate was significantly higher in the placebo group at 3 and 6 months vs baseline. The reason for this was probably that the pacing rate had to be increased in some patients to obtain capture. The mean heart rate was identical in both groups at the 12-month investigation.
Evaluation during matched pacing
Similar to investigations of spontaneous heart rate, systolic blood pressure and ejection fraction increased in the metoprolol groups (Figs 1 and 2) . Likewise, the beta-blocker treated patients had a significant increase in peak ejection rate.
Although a non-significant increase in peak filling rate was noted in the beta-blocker group from 3 months and onward, only the placebo group had a significant increase at 3 months of follow-up. No change was observed in the placebo group at 6 or 12 months.
Heart rate and beta-blockade 577 Left ventricular volumes decreased gradually and reached maximal effects by 6 months of follow-up (Table 3 , Fig. 3 ).
As noted in previous studies with beta-blockers in heart failure, the response to metoprolol treatment was variable in the individual patient. The skewness in data is demonstrated in a box plot (Fig. 3) , in which patients with different aetiologies of heart failure are shown separately. In contrast to the placebo group, volume data in patients on metoprolol (mean values, as well as median and percentile values) were consistently reduced after 6 months of treatment.
An estimation of the force-frequency relationship, as expressed by the relationship between peak ejection rate and heart rate, was plotted for both treatment groups (Fig. 4) . The relationship was elevated in the metoprolol-treated group after 12 months of treatment, but was unchanged in the placebo group.
Discussion
The results of this study suggest that when myocardial recovery has been achieved by metoprolol, the improved cardiac function is not negatively affected by a higher heart rate. The maintenance of cardiac performance at a higher heart rate may suggest an improvement in the force-frequency relationship, related to a restoration of cardiac performance.
Diastolic function
There was no statistically significant difference in the early diastolic rapid filling rate, as assessed by radionuclide angiography. Similar findings have been observed in patients treated with carvedilol [16] . In a previous study using transmitral Doppler recordings, we showed that the restrictive filling pattern, as expressed by a short early inflow E wave deceleration time, was alleviated by metoprolol treatment [12] . An evaluation of left ventricular isovolumic relaxation rate in the same study did not show any effects of metoprolol treatment. Similarly, Eichhorn and co-workers have provided negative data concerning beta-blocker treatment and effects on isovolumic relaxation [9] . We postulated that an improvement in diastolic function by metoprolol treatment was obtained through the lengthening of the early diastolic filling time, and not by an increase in the speed of relaxation. Although a rapid early peak filling rate is normally considered a sign of adequate diastolic function, the opposite might be observed in cases of severe left ventricular failure and with a restrictive filling pattern [7, 17, 18] . Radionuclide data are based on changes in volume normalized for end-diastolic volume. During myocardial recovery the decrease in end-diastolic volume and increase in stroke volume might obscure true changes in myocardial relaxation rate. Measurement of peak filling rate is difficult in patients with high heart rates and low stroke volumes, and it could not be excluded that minor effects were present, as expressed by the non-significant increase in the metoprolol group during pacing investigations. However, the present results support our previous data, indicating that major diastolic effects are not achieved through an enhancement of maximal early rapid filling rate. On the contrary, a prolongation of early rapid filling time might ensure a more thorough relaxation and therefore be a prerequisite for restoration of low intracellular calcium concentration. Hypothetically, an increase in sarcoplasmatic reticulum calcium stores could subsequently be the basis for an improvement in systolic performance [19, 20] . In an experimental model it has been suggested that beta-blocker therapy can increase sarcoplasmic reticulum Ca 2+ ATPase activity [21] . Although the present data suggest that left ventricular function is not dependent on a low heart -on a shortterm basis -it is most likely that the long-term reduction in heart rate and associated changes in diastolic function and myocardial metabolism are of major importance for myocardial recovery. It would also be anticipated that a long-term increase in heart rate should lead to a deterioration in myocardial performance. Heart rate and beta-blockade 579 Table 3 Heart rate, blood pressure, and radionuclide variables expressing systolic and diastolic function during matched paced heart rate in patients treated with metoprolol or placebo 
Systolic function
In contrast to the absence of changes in peak filling rate, indices of systolic function -such as ejection fraction and peak ejection rate -clearly improved during metoprolol treatment. The positive effects on systolic function were present irrespective of heart rate. The increase Heart rate Peak ejection rate (EDV.s Circles denote data at spontaneous heart rate and triangles denote data at matched atrial pacing. The solid arrow shows the transition from spontaneous heart rate to a higher heart rate during pacing. The dashed arrow shows the hypothetical transition if the improvement after beta-blockade would have been a mere effect of a lower heart rate.
Heart rate and beta-blockade 581 in heart rate causes an increase in contractility [22] and this effect is depressed in the failing heart [23] . An improvement of inotropic reserve following metoprolol treatment has previously been suggested [24] . It has been shown that the optimal force-frequency relationship is present at a lower frequency in failing myocardium as compared to non-failing myocardial preparations [10, 11] . Therefore, the ability to maintain cardiac systolic performance during a higher heart rate may suggest a shift in the force-frequency relationship after metoprolol treatment toward a more normal pattern. If the improvement in cardiac performance had merely been secondary to the decrease in heart rate, the atrial pacing procedure should have been associated with a fall in peak ejection rate to a level comparable to baseline measurements, as denoted by the dashed arrow in Fig. 4 . Whether these investigations at two different heart rates represented the ascending or descending limb of the force-frequency relationship was not possible to discern in this study [25] . Several pacing steps should have been necessary for such an evaluation. Peak ejection rates do not represent actual myocardial force generation, but are an index of contractility. However, in the view of the increase in systolic blood pressure it is likely that peak ejection rates reflect a true increase in force development. We have previously shown that the increase in blood pressure caused by metoprolol treatment is associated with unchanged peripheral resistance at rest [8] . It could not be excluded that atrial pacing might be associated with an increase in peripheral resistance, although no negative signs of any possible increase in afterload were observed. On the contrary, the beneficial attenuation of left ventricular remodelling was observed during pacing ( Fig. 3) as well as at spontaneous heart rate.
It is possible that an upregulation of the beta 1-receptors, a property possessed by some beta-blockers including metoprolol [26] , might have contributed to the increase in left ventricular performance. An improvement of inotropic reserve following metoprolol treatment has previously been suggested using dobutamine infusion [24] . Additionally, Bö hm and co-workers recently showed a possible post-receptor improvement following metoprolol treatment using milrinone infusion [27] . Therefore both receptor and post-receptor events appear to be improved after metoprolol treatment. In the present study we demonstrated that a third mechanism for inotropy, the Treppe effect, also showed signs of restoration after long-term metoprolol treatment.
An ability to maintain cardiac performance at higher heart rates after metoprolol treatment might account for the observed improvement in exercise capacity [8, 13, 28] . Beta-blockers that do not upregulate the beta-receptors have not been associated with improvement in exercise capacity [29] . Whether carvedilol has any influence on inotropic reserve, is presently unknown.
Limitations of the study
Transoesophageal pacing cannot produce a state equal to a physiological increase in heart rate. Furthermore, the patients experienced some retrosternal discomfort during the pacing procedure, which might have altered sympathetic tone. However, it should be anticipated that this discomfort is equal in severity in both groups, and during repeated investigations.
In the present study, we included a group of patients on open treatment to increase the group of investigated patients, and the two groups of metoprolol treated patients displayed minor differences. Some differences with respect to treatment effects were also observed. However, the major trends were similar in both groups, suggesting that beta-blockade might exert positive effects in patients with varying aetiologies of heart failure and with varying degrees of ventricular dysfunction. At the time of initiation of this study, positive effects of beta-blockade in patients with heart failure secondary to ischaemic heart disease had not been conclusively shown. Recent studies have shown that carvedilol and metoprolol might be equally effective in patients with ischaemic aetiology [30, 31] .
Conclusions
We have shown that the improvement in cardiac function achieved by long-term metoprolol treatment was maintained during a short-term increase in heart rate achieved by atrial pacing. These findings suggest an improvement of the depressed force-frequency relationship by metoprolol treatment.
